The Enterprise Value as of September 2024 (TTM) for ImmunoGen, Inc. (IMGN) is 8.19B

According to ImmunoGen, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 8.19B. This represents a change of 217.81% compared to the average of 2.58B of the last 4 quarters.

ImmunoGen, Inc. (IMGN) Historical Enterprise Value (quarterly & annually)

How has IMGN Enterprise Value performed in the past?

The mean historical Enterprise Value of ImmunoGen, Inc. over the last ten years is 684.03M. The current 8.19B Enterprise Value has changed 119.66% with respect to the historical average. Over the past ten years (40 quarters), IMGN's Enterprise Value was at its highest in in the June 2023 quarter at 4.47B. The Enterprise Value was at its lowest in in the December 2016 quarter at 17.72M.

ImmunoGen, Inc. (IMGN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of ImmunoGen, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ImmunoGen, Inc. (IMGN) Average Enterprise Value

How has IMGN Enterprise Value performed in the past?

The current Enterprise Value of ImmunoGen, Inc. (IMGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

ImmunoGen, Inc. (IMGN) Enterprise Value vs. Peers

How is IMGN’s Enterprise Value compared to its peers?

ImmunoGen, Inc.’s Enterprise Value is greater than Madrigal Pharmaceuticals, Inc. (4.91B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than TG Therapeutics, Inc. (3.44B), greater than Terns Pharmaceuticals, Inc. (458.36M), greater than Hepion Pharmaceuticals, Inc. (2.24M), greater than Viking Therapeutics, Inc. (5.95B), greater than Axsome Therapeutics, Inc. (4.35B), greater than Seres Therapeutics, Inc. (286.75M), greater than Mereo BioPharma Group plc (582.99M), greater than PDS Biotechnology Corporation (74.53M), greater than Inozyme Pharma, Inc. (343.89M), greater than HOOKIPA Pharma Inc. (87.25M), greater than eFFECTOR Therapeutics, Inc. (3.83M), greater than X4 Pharmaceuticals, Inc. (40.79M), greater than Elevation Oncology, Inc. (8.41M), greater than Akero Therapeutics, Inc. (1.56B), greater than Reata Pharmaceuticals, Inc. (6.68B),

Build a custom stock screener for ImmunoGen, Inc. (IMGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunoGen, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ImmunoGen, Inc. (IMGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ImmunoGen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.